This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 0008-5472.CAN-08-2762v1 69/3/845    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jiang, T. Articles by Ball, D. W. Search for Related Content PubMed PubMed Citation Articles by Jiang, T. Articles by Ball, D. W.

Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer

Departments of ¹ Oncology, ² Surgery, and ³ Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

Requests for reprints: Douglas W. Ball, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-4789; Fax: 410-614-9884; E-mail: dball{at}jhmi.edu.

Key Words: ASCL1 • small cell lung cancer • CD133 • Aldehyde dehydrogenase

The basic helix-loop-helix transcription factor achaete-scute complex homologue 1 (ASCL1) is essential for the development of normal lung neuroendocrine cells as well as other endocrine and neural tissues. Small cell lung cancer (SCLC) and non-SCLC with neuroendocrine features express ASCL1, where the factor may play a role in the virulence and primitive neuroendocrine phenotype of these tumors. In this study, RNA interference knockdown of ASCL1 in cultured SCLC resulted in inhibition of soft agar clonogenic capacity and induction of apoptosis. cDNA microarray analyses bolstered by expression studies, flow cytometry, and chromatin immunoprecipitation identified two candidate stem cell marker genes, CD133 and aldehyde dehydrogenase 1A1 (ALDH1A1), to be directly regulated by ASCL1 in SCLC. In SCLC direct xenograft tumors, we detected a relatively abundant CD133^high-ASCL1^high-ALDH1^high subpopulation with markedly enhanced tumorigenicity compared with cells with weak CD133 expression. Tumorigenicity in the CD133^high subpopulation depended on continued ASCL1 expression. Whereas CD133^high cells readily reconstituted the range of CD133 expression seen in the original xenograft tumor, CD133^low cells could not. Our findings suggest that a broad range of SCLC cells has tumorigenic capacity rather than a small discrete population. Intrinsic tumor cell heterogeneity, including variation in key regulatory factors such as ASCL1, can modulate tumorigenicity in SCLC. [Cancer Res 2009;69(3):845–54]